Background

Addressing “undruggable” intracellular targets in oncology

About us

We are a biopharmaceutical company devoted to the development of a new class of therapeutics to address unmet medical needs in cancer.

Ribeira Sacra

Libera Bio aims at changing cancer therapy by allowing biologics to cross the cell membrane and reach “undruggable” intracellular targets:  the “Holy Grail” in oncology

Libera Bio leverages  its unique proprietary nanotechnology to hold and protect biologicals (e.g., antibodies) in the blood stream following IV administration and to deliver them intracellularly to tumor cells and to metastatic cells

Libera Bio seeks to maximize the use of its technology with oncology biopharma partners, to offer patients new oncology breakthrough treatments based on intracellular delivery of biologics

Our team

Olivier R. Jarry
Olivier R. Jarry

CEO

María José Alonso
María José Alonso Fernández

CSO

Desiree Teijeiro
Desirée Teijeiro Osorio

COO

Discover our MPN Technology®

Our patented MPN Technology® enables the discovery and development of new compounds involving intracellular biologics, especially monoclonal antibodies (mAbs), to successfully engage previously undruggable targets.

Infografía
Imagen paciente

Programs

Libera Bio lead target is Mutated KRAS:

KRAS is the Most Frequently Mutated Gene in Human Cancer (e.g. in 9 out of 10 Pancreatic Ductal Adenocarcinoma – PDAC)

The presence of mutant KRAS is associated with poor prognosis and resistance to chemotherapy and targeted treatments (e.g. EGFR)

Despite this important Unmet Medical Need, the development of effective anti-RAS therapies has been marred by more than three decades of failure

Tabla Pipeline
Tabla

Partnering & Investors

Libera Bio is open to licensing or partnering its MPN Technology® to develop or co-develop new cancer treatments based either on biologics or small molecules.

Partnering contact: Olivier Jarry, partnering@liberabio.com

Inquiries from potential investors in the next round of funding of Libera Bio are welcome.

Investors Relations: partnering@liberabio.com

News

Supported by

Axudas IGAPE Galicia Exporta Empresas
Bioincubatech
Camaras Union Europea
ignicia
Xunta Gain
HealthtechTAB
Bioga

Contact us and follow us on social media

Libera Bio Santiago de Compostela

EUROPE
Edificio Emprendia
Avenida do Mestre Mateo 2
15706 Santiago de Compostela, A Coruña (Spain)

Libera Bio New York

NORTH AMERICA
15 Rockridge Rd
Larchmont NY 10538-3918
(USA)

Persoal cofinanciado pola Xunta de Galicia ao abeiro da Resolución da Axencia Galega de Innovación do 29 de maio de 2019 (Programa Talento Sénior)

Xunta Galicia
Talento senior